API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
EU WC
0
Listed Suppliers
0
0
0
USA (Orange Book)
0
Europe
0
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
0
USFDA Orange Book Patents
0
USFDA Exclusivities
0
Blog #PharmaFlow
0
News
EDQM
0
USP
0
JP
0
Other Listed Suppliers
0
0
Details:
LN-145 is a ready-to-infuse TIL therapy that utilizes an autologous TIL manufacturing process, as originally developed by the NCI and further optimized by Iovance for the treatment of patients with metastatic NSCLC.
Lead Product(s): LN-145
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 04, 2024
Details:
LN-145 TIL therapy for patients who have progressed on or after chemotherapy and anti-PD-1 therapy for advanced (unresectable or metastatic) NSCLC without EGFR, ROS or ALK genomic mutations
Lead Product(s): LN-145,Cyclophosphamide,Fludarabine Phosphate
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 10, 2023
Details:
TIL product candidate, LN-145 for metastatic melanoma, has the potential to become the first approved one-time cell therapy for a solid tumor cancer. The Iovance TIL platform has demonstrated promising clinical data across multiple solid tumors.
Lead Product(s): LN-145
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable March 08, 2022
Details:
The first Iovance clinical study participant infused with LN-145, a TIL cell therapy manufactured at iCTC is enrolled in a metastatic non-small cell lung cancer (mNSCLC) cohort in the IOV-COM-202 basket study in solid tumors.
Lead Product(s): LN-145
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable September 23, 2021
Details:
This phase II trial studies how well autologous tumor infiltrating lymphocytes LN-145 works in treating patients with ovarian cancer, anaplastic thyroid cancer, osteosarcoma, or other bone and soft tissue sarcomas that do not respond to treatment.
Lead Product(s): LN-145
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 29, 2021
Details:
Company presented new interim clinical data for the tumor infiltrating lymphocyte therapy LN-145 in combination with pembrolizumab in advanced, recurrent, or metastatic head and neck squamous cell carcinoma who are immune checkpoint inhibitor naive.
Lead Product(s): LN-145,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable November 09, 2020
Details:
Safety and efficacy of tumor infiltrating lymphocytes (TIL; LN-145) in combination with pembrolizumab for advanced, recurrent or metastatic HNSCC, will be discussed in the at Society for Immunotherapy of Cancer (SITC) 35th Annual Meeting.
Lead Product(s): LN-145,Pembrolizumab
Therapeutic Area: Oncology Product Name: LN-145
Highest Development Status: Phase IIProduct Type: Cell and Gene therapy
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable October 14, 2020